司库奇尤单抗对银屑病关节炎附着点骨赘和骨侵蚀进展的影响:一项为期一年、采用高分辨率外周定量计算机断层扫描的双盲随机安慰剂对照试验
这项4期双盲随机安慰剂对照试验纳入40例活动性银屑病关节炎且第2至4掌指关节至少1处骨侵蚀的患者,1:1皮下注射司库奇尤单抗或安慰剂,采用高分辨率外周定量CT于基线、第24周和第48周评估。司库奇尤单抗组骨侵蚀体积显著减少而安慰剂组无变化,附着点骨赘进展的OR为0.264,部分骨侵蚀愈合的OR为2.882。
要点
- 司库奇尤单抗组骨侵蚀体积中位变化-0.1 vs 安慰剂组0.0,P=0.004。
- 司库奇尤单抗组附着点骨赘进展OR 0.264(95%CI 0.080-0.878,P=0.030)。
- 司库奇尤单抗组部分骨侵蚀愈合OR 2.882(95%CI 1.130-7.349,P=0.027)。
核心结论
- 司库奇尤单抗在促进部分骨侵蚀修复和阻止银屑病关节炎附着点骨赘进展方面显示出潜在获益。
研究设计与样本
- 4期双盲随机安慰剂对照试验,纳入40例活动性银屑病关节炎且第2至4掌指关节至少1处骨侵蚀的患者,1:1随机分配至皮下司库奇尤单抗或安慰剂组。
- 于基线、第24周和第48周对第2至4掌指关节行高分辨率外周定量计算机断层扫描。
- 主要结局为第24周和第48周高分辨率外周定量CT测量的第2至4掌指关节骨侵蚀体积变化。
- 34例完成研究治疗的患者纳入符合方案分析。
主要发现
- 患者平均±标准差年龄51.9±13.4岁,男性20例(50%),平均±标准差病程4.7±6.7年。
- 基线、第24周和第48周时,司库奇尤单抗组骨侵蚀体积显著减少,而安慰剂组无变化(司库奇尤单抗组中位变化-0.1[四分位距-0.5至0.0] vs 安慰剂组0.0[四分位距-0.2至0.4],P=0.004)。
- 司库奇尤单抗组附着点骨赘体积变化呈类似趋势,而安慰剂组无差异(司库奇尤单抗组中位变化-0.1[四分位距-0.8至0.0] vs 安慰剂组0.0[四分位距-0.4至1.3],P=0.067)。
- 广义估计方程结果显示,司库奇尤单抗组附着点骨赘进展的比值比(OR)为0.264(95%置信区间0.080-0.878,P=0.030)。
- 司库奇尤单抗组部分骨侵蚀愈合的OR为2.882(95%置信区间1.130-7.349,P=0.027)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high-resolution peripheral quantitative computed tomography (HR-pQCT). METHODS: This was a phase 4, double-blind, randomized, placebo-controlled trial. Patients with active PsA and ≥1 erosion in metacarpophalangeal joints (MCPJs) 2 to 4 were randomly assigned in a 1:1 ratio to subcutaneous secukinumab or placebo. HR-pQCT of MCPJs 2 to 4 were performed at baseline, week 24, and week 48. The primary outcome was the changes in the volume of erosions on MCPJs 2 to 4 measured by HR-pQCT at 24 and 48 weeks. RESULTS: Forty patients (mean ± SD age 51.9 ± 13.4 years, 20 [50%] male, mean ± SD disease duration 4.7 ± 6.7 years) were recruited. Thirty-four patients who completed study treatment were included in the per-protocol analysis. At baseline, week 24, and week 48, the secukinumab group showed a significant reduction in erosion volume, whereas no changes were observed in the placebo group (median change in the secukinumab group -0.1 [interquartile range -0.5 to 0.0] vs 0.0 [interquartile range -0.2 to 0.4] in the placebo group, P = 0.004). A similar trend was observed for enthesiophyte volume changes in the secukinumab group, whereas no differences were noted in the placebo group (median change in the secukinumab group -0.1 [interquartile range -0.8 to 0.0] vs 0.0 [interquartile range -0.4 to 1.3] in the placebo group, P = 0.067). Generalized estimating equations results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% confidence interval [CI] 0.080-0.878, P = 0.030), whereas the OR for partial erosion healing in the secukinumab group was 2.882 (95% CI 1.130-7.349, P = 0.027). CONCLUSION: Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.
引用
- Jin Y, Cheng IT, So H, et al. Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography. Arthritis Rheumatol. 2025. PMID: 40083242. doi:10.1002/art.43154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。